Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.

about

Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.

Item

http://www.wikidata.org/entity/Q40118662

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Patient factors associated wit ...... en with detrusor overactivity.

@en

type

Item

label

Patient factors associated wit ...... en with detrusor overactivity.

@en

prefLabel

Patient factors associated wit ...... en with detrusor overactivity.

@en

P1476

Patient factors associated wit ...... en with detrusor overactivity.

@en

P2093

Christopher Mayne

http://www.w3.org/2001/XMLSchema#string

Douglas G Tincello

http://www.w3.org/2001/XMLSchema#string

Mark Slack

http://www.w3.org/2001/XMLSchema#string

P2860

A simulation study of the number of events per variable in logistic regression analysis.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.

Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder.

Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability.

Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.

Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.

P304

426-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/NAU.22948

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Keith R. Abrams

Rhiannon K Owen

P577

2016-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26756171

http://www.w3.org/2001/XMLSchema#string